BIT’s 5th Annual Symposium of Drug Delivery Systems

Title: Fibroblasts as a Bio-cellular Model for Studying Amino Acids Transport in Schizophrenia, Bipolar and Related CNS Disorders

Dr. Nikolaos Venizelos*, Chang-Ren Chen, and Nguyen Vu Lan
Director
Örebro University
Sweden

Abstract

Tyrosine and tryptophan are precursors to dopamine and serotonin and are involved in partial regulation of dopamine and serotonin synthesis. Changes in tyrosine and or tryptophan availability may influence dopamine-serotonin function that may cause widespread changes both in neurotransmission and psychopathology in patients with schizophrenia, bipolar-I and related CNS disorders. Competitive transport with other amino acids or aberrant transport of these precursors across the cell membranes/blood brain barrier (BBB) can cause a limited availability of tyrosine and/or tryptophan to the brain. Transport of neutral amino acids including tyrosine, tryptophan and alanine, mainly occurs through L and A system. Aberrant tyrosine transport in schizophrenia, bipolar-I disorders and autism, results from different investigations, functionality and the relationship between tyrosine, tryptophan and alanine transport in fibroblasts will be presented and discussed.

Biography

Dr. Nikolaos Venizelos, Medicine Doctor (Ph.D.-medicine),now is an Associate professor of Biomedicine, head of the Neuropsychiatric Research Laboratory and Bio-bank of the Department, Chairman for Research Board of Biomedicine Program director of Biomedicine education program, Member of the Sweden's National Bio-banks Council. He got his B Sc in biomedicine, M Sc in cell biology, Specialist in clinical chemistry, Medicine Doctor's degree (Ph.D.) at Karolinska Institute, Docent. And Dr. Nikolaos Venizelos got the Norage-Pharmacia Award in 1994, and a Research Award from “Intern. Neuropsychiatry Congress (INA-WFSBP)”, Athens, 2004. Currently Dr. Nikolaos Venizelos’ researches focus on the Bio-cellular membrane and amino acid transporters in Neuropsychiatric disorders. Studies on the mechanisms of cellular membrane transport of dopamine and serotonin precursors in schizophrenia, Medicine Doctor (Ph.D.-medicine), now is an Associate professor of Biomedicine, head of the Neuropsychiatric Research Laboratory and Bio-bank of the Department, Chairman for Research Board of Biomedicine Program director of Biomedicine education program, Member of the Sweden's National Bio-banks Council. He got his B Sc in biomedicine, M Sc in cell biology, Specialist in clinical chemistry, Medicine Doctor's degree (Ph.D.) at Karolinska Institute, Docent. And Dr. Nikolaos Venizelos got the Norage-Pharmacia Award in 1994, and a Research Award from “Intern. Neuropsychiatry Congress (INA-WFSBP)”, Athens, 2004. Currently Dr. Nikolaos Venizelos’ researches focusate professor of Biomedicine, head of the Neuropsychiatric Research Laboratory and Bio-bank of the Department, Chairman for Research Board of Biomedicine Program director of Biomedicine education program, Member of the Sweden's National Bio-banks Council. He got his B Sc.

+ show speakers and program
Track 1: Global Policy, Market Trend, Business Development and of DDS
Track 2: Breaking Research and Innovative DDS Technologies
Session 2-1: Sustained, Delayed-Release, Controlled or Modified-release Drug Delivery
Session 2-2: Targeted Delivery Technologies
Session 2-3: Drug Delivery Development of Poorly Soluble Drugs
Session 2-4: Optimal Formulation Strategies to Improve Drug Bioavailability
Session 2-5: New Biocompatible Polymers, Biopolymers and Bioabsorbable Intelligent Materials
Session 2-6: Lipid based drug delivery systems
Session 2-7: Targeting Anticancer Drug Delivery
Session 2-8: Drugs and Devices for Delivery to the Central Nervous System
Session 2-9: New Methods for the Production of Particles, Capsules, and Coatings
Session 2-10: DDS Technologies for Self-assembly
Session 2-11: Predictive Informatics and IT in Drug Delivery System Design
Session 2-12: Prodrugs for Better Efficacy
Session 2-13: New Manufacturing of Microcapsules
Session 2-14: Implantable Drug Delivery Systems
Session 2-15: Patient-Centric Drug Delivery
Session 2-16: Innovative Technologies in DDS Process Development
Track 3: Innovative DDS Technology Targeting Different Route of Administration
Session 3-1: New Oral, Transmucoadhesive and Buccal Drug Delivery
Session 3-2: New Nasal and Pulmonary Drug Delivery
Session 3-3: New Transdermal Patch and Topical Drug Delivery
Session 3-4: New Ocular Drug Delivery
Track 4: Novel Technologies for Biotherapeutic Drug Delivery
Session 4-1: New Carriers for Biotherapeuticals
Session 4-2: Advanced Polymeric Carriers for Peptide/Proteins Drugs
Session 4-3: RNAi, Gene Therapeutics, Nucleic Acid and Cell Therapy
Session 4-4: Vaccine Carriers, Mucosal Barriers and Immunotherapy
Track 5: Nanotechnologies for Drug Delivery Systems
Session 5-1: Biopharmaceutical, Physiological and Clinical Considerations for Nanotechnology in Drug Delivery
Session 5-2: Drug Targeting and Nanomedicines
Session 5-3: Biocompatible and Biodegradable Materials, Dendrimers for Drug Nanoparticles
Session 5-4: Nano-Architectures/Structures: Nanotubes, Nanorods, Nanofiber Scaffolds and Fullerenes for Nanomedicine
Session 5-5: Nanotechnology for the Delivery of Small Molecules
Session 5-6: Nanocarriers in Medicine : Challenges, Dogmas and New Horizons
Track 6: Medical Devices for Drug Delivery, Surgery and Therapy
Session 6-1: Latest Breakthroughs in Drug Delivery Systems and Smart Drug Release Devices
Session 6-2: Development and Manufacturing of Inhalation Devices
Session 6-3: Prefilled Syringes and Injection Devices
Session 6-4: Needle-Free, Needle Array and Safety Syringe Drug Delivery Systems
Session 6-5: Insulin Delivery Devices
Session 6-6: Drug Eluting Stent Technologies
Session 6-7: Image-guided Drug Delivery
Session 6-8: Vaginal Ring and Intrauterine Device

20 Oct - 22 Oct 2015
Beijing
China
meeting website